Breast Biopsy Market Overview:
Global Breast Biopsy Market was valued at $976.7 million in 2016, and is projected to reach at $1,420 million by 2023, growing at a CAGR of 5.3% from 2017 to 2023. Breast biopsy is a test performed to remove tissue or fluid from the suspicious area of the patient’s body, while the removed sample is further examined to check the presence of breast cancer. There are different types of biopsy procedures depending on the product, such as vacuum assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB), recommended by the doctor based on the location, size, and other characteristics of the breast abnormality.
Increase in incidence of breast cancer; ageing women especially around the age 40, during menopause (are more susceptible to breast cancer); and growth in awareness regarding breast cancer screening programs drive the market growth. However, uncertain regulatory issues, infection risks associated during breast biopsy procedures, and unclear reimbursement policies are the factors limiting the market growth. Conversely, emergence of technologically advanced and minimally invasive breast biopsy devices are expected to provide lucrative opportunities in untapped market.
Global Breast Biopsy Market Segmentation
The breast biopsy market is segmented based on product, image guided technology, end user, and geography. On the basis of product, it is categorized into vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). Based on image guided technology, it is classified into MRI-guided biopsy, ultrasound guided biopsy, mammography guided stereotactic biopsy, CT-guided biopsy, and others. On the basis of end user, it is bifurcated into diagnostic centers and hospitals. Geographically, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Germany, Russia, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, Singapore, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Israel, Saudi Arabia, South Africa, and rest of LAMEA).
Drivers, Restraints, and Opportunities
The impact of the driving factors is expected to surpass that of the restraints. Moreover, emergence of new technologies and increase in adoption of mammography-guided stereotactic biopsy are anticipated to provide new growth opportunities in the near future.
Global Breast Biopsy Market: Drivers, Restrains, and Opportunities
The mammography-guided stereotactic biopsy segment accounted for a significant share in the global biopsy market, and is expected to maintain dominance during the forecast period.
Breast Biopsy Market by Image Guided Technology
Breast cancer is one of the significant health issues for women globally. This is evident from the estimated number of new breast cancer cases from American Cancer Society, Inc., in 2015, which stated the newly diagnosed cancer based on age (in situ, invasive cases, and total deaths) in the U.S. In addition, more than 3.1 million women were alive on January 1, 2014, with a history of breast cancer in the U.S. alone.
Estimated Number of Female Breast Cancer Cases and Deaths by Age, U.S., 2015
The recommendation for breast biopsy especially the mammography guided stereotactic biopsy has rapidly increased the adoption rate in the developed countries. Moreover, the rationalizing use of mammography complemented by the other breast examinations has served as a pillar for screening breast cancer for past few years driving the market growth.
The list of key players included in the report include Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.
The other players in the value chain include Zenalux Biomedical, Inc., F. Hoffmann-La Roche Ltd., OncoCyte Corporation, Laboratory Corporation of America Holdings (Labcorp), Scion Medical Technologies, Planmed Oy, Aurora Imaging Technology Inc., Carestream Health, Cardinal Health, and PerkinElmer.
Key Benefits for Stakeholders
- This report provides an extensive analysis of the current & emerging market trends and dynamics in the global breast biopsy market.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Region- and country-wise market conditions are analyzed in the report.
Breast Biopsy Market Key Segments
- Vacuum Assisted Biopsy (VAB)
- Core Needle Biopsy (CNB)
- Fine Needle Aspiration Biopsy (FNAB)
By Guided Technology
- MRI-Guided Biopsy
- Ultrasound Guided Biopsy
- Mammography Guided Stereotactic Biopsy
- CT-Guided Biopsy
By End User
- Diagnostic Centers
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA